Omega 3 PUFA

DRUG2 trials

Sponsors

Oregon Health and Science University, Faculty of medicine of Tanta university

Conditions

Age Related Cognitive DeclineAlzheimer's DiseaseEndothelial DysfunctionExecutive DysfunctionPaediatricsVascular Dementia

Phase 2

n-3 PUFA for Vascular Cognitive Aging

Oregon Health and Science UniversityAge Related Cognitive Decline, Alzheimer's Disease, Endothelial Dysfunction +2

Start: 2014-05-31End: 2021-06-30Updated: 2020-09-04

Phase 4

Protective Role of Some Dietary Supplements in Children with Bronchial Asthma

Active, not recruitingPACTR202412555287430

Faculty of medicine of Tanta universityPaediatrics

Start: 2021-04-01Target: 150Updated: 2026-09-14

Related Papers

ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults

JAMA Network Open2024-08-0112 citations

Randomized trial of n‐3 PUFA for cerebral white matter hyperintensities, medial temporal lobe atrophy and white matter integrity in older non‐demented adults: Per‐protocol and ApoE stratified results

Alzheimer s & Dementia2021-12-01

P2‐305: Omega 3 fatty acids for the prevention of vascular cognitive aging: Methods and rationale for a phase II trial

Alzheimer s & Dementia2015-07-014 citations